home / lobbying

lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

293 rows where filing_period = "third_quarter", filing_year = 2023 and issue_code = "PHA" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: filing_type, income_amount, is_termination, received_date (date)

issue_code 1

  • PHA · 293 ✖

filing_year 1

  • 2023 · 293 ✖

filing_period 1

  • third_quarter · 293 ✖
id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
3041761 NORIDIAN MUTUAL INSURANCE COMPANY c5ef4861-5d28-4527-83b0-cf1099a2e8d0 3T NORIDIAN MUTUAL INSURANCE COMPANY 6473 NORIDIAN MUTUAL INSURANCE COMPANY 2023 third_quarter PHA INSULIN Act: Insulin Out of Pocket Charges S. 150 - Affordable Prescriptions for Patients Act of 2023 HOUSE OF REPRESENTATIVES,SENATE     0 1 2023-08-14T13:04:15-04:00
3044446 STONINGTON GLOBAL 82ef916b-1266-4094-80ca-bb9985cadde2 3T STONINGTON GLOBAL 401105189 SORRENTO THERAPEUTICS, INC. 2023 third_quarter PHA Promoting non-opioid pain management alternatives. Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office     0 1 2023-10-03T14:11:36-04:00
3044662 2359 STRATEGIES 176c568f-4c61-4d23-a80e-fa1a6ed97aec Q3 2359 STRATEGIES 401106114 TRAVERE THERAPEUTICS 2023 third_quarter PHA Orphan Drug Act HOUSE OF REPRESENTATIVES,SENATE 22500   0 0 2023-10-04T10:43:57-04:00
3044714 WATKINS & EAGER PLLC b915aaef-b8fc-42dc-bebf-12f93c1b2adf Q3 WATKINS & EAGER PLLC 401104403 ZYNERBA PHARMACEUTICALS, INC. 2023 third_quarter PHA Encourage Members to act favorably on matters of importance to Zynerba at their direction; Trial for medication that could help individuals with Fragile X Syndrome. HOUSE OF REPRESENTATIVES,SENATE 45000   0 0 2023-10-04T11:16:34-04:00
3044785 AMERICAN COLLEGE OF CLINICAL PHARMACY 82c25e29-3255-4516-9a33-602545b2ebf9 Q3 AMERICAN COLLEGE OF CLINICAL PHARMACY 57258 AMERICAN COLLEGE OF CLINICAL PHARMACY 2023 third_quarter PHA Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs. HOUSE OF REPRESENTATIVES,SENATE   144981 0 0 2023-10-04T14:08:32-04:00
3045001 PENN AVENUE PARTNERS 577158e9-5468-4f64-bb01-7400828fa42b Q3 PENN AVENUE PARTNERS 400918672 ALKERMES, INC. 2023 third_quarter PHA Regulatory and legislative issues impacting Alkermes. Appropriations. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2023-10-04T20:18:02-04:00
3045049 PENN AVENUE PARTNERS 22fe6e65-2e21-4ae8-a484-08f2789d5514 Q3 PENN AVENUE PARTNERS 400918672 UNITEDHEALTH GROUP, INC. 2023 third_quarter PHA Pharmacy benefit related issues. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office 90000   0 0 2023-10-05T07:09:10-04:00
3045389 MCDERMOTT+ LLC 818c5795-b79f-4960-8db5-36cade838292 Q3 MCDERMOTT+ LLC 401103287 ALLIANCE FOR RURAL HOSPITAL ACCESS 2023 third_quarter PHA Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-10-06T10:04:06-04:00
3045519 THE MADISON GROUP 65c252ed-4f63-48d7-bf9d-5c27286a0c94 Q3 THE MADISON GROUP 284050 WALGREEN CO. 2023 third_quarter PHA Issues pertaining to the retail pharmacy industry, access to and delivery of COVID-19 vaccinations and pharmacy benefit managers (PBMs). H.R. 1770, the Equitable Community Access to Pharmacist Services Act; Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-10-06T11:45:54-04:00
3045555 MR. H.R. BERT PENA 4c5c8c32-2649-4ca6-8698-ed2c5004d632 Q3 MR. H.R. BERT PENA 400323519 MARGO RX LLC(DBA RICHARD'S PHARMACY) 2023 third_quarter PHA PBM AND DRUG PRICES Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES     0 0 2023-10-06T11:57:26-04:00
3045605 FROST BROWN TODD LLC 116ceefa-cf61-413c-8351-7ea63ec0bd7e Q3 FROST BROWN TODD LLC 283572 DISPOSERX 2023 third_quarter PHA Support Act Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2023-10-06T13:26:13-04:00
3045696 REPUBLIC CONSULTING, LLC 01c099c1-1135-4f1c-9d07-87e8519d351e Q3 REPUBLIC CONSULTING, LLC 401016871 IQVIA 2023 third_quarter PHA Monitor Health Data Policy. Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-10-06T15:13:20-04:00
3045796 DENTONS US LLP ae59222c-bc9a-4499-9aab-f2641933d265 Q3 DENTONS US LLP 36105 PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION (PILMA 2023 third_quarter PHA Federal issues impacting workforce and innovation in the pharmaceutical industry. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2023-10-06T16:52:59-04:00
3045950 RED+BLUE STRATEGIES 5bda4cac-4e0b-4968-ac9a-e167f8c21c1d Q3 RED+BLUE STRATEGIES 400693064 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2023 third_quarter PHA H.R. 3561 - The PATIENT Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors. H.R. 5378 - Lower Costs, More Transparency Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors. S. 2973 - Modernizing and Ensuring PBM Accountability Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors. S. 1967 - The PBM Act - Issues related to delinking and limiting current tools used by PBMS to manage pharmacy benefits in Medicare. S. 1339 - The Pharmacy Benefit Manager Reform Act - Issues focused on limiting spread pricing and requiring rebate pass through and other tools used to control the price of prescription medications. S. 127 - The PBM Transparency Act - Issues related to the study of Pharmacy Benefit Managers by the Federal Trade Commission. S. 150 - Affordable Prescriptions for Patients Act - Issues related to ensuring that people's access to affordable medications are not impeded and innovations to ensure fair pricing structures are promulgated to their fullest. Issues related to prescription drug supply chain integrity and transparency. Issues related to the implementation of the Inflation Reduction Act for purposes of ensuring access to affordable medications for Medicare beneficiaries and people across the United States. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 70000   0 0 2023-10-07T14:44:38-04:00
3045986 RED+BLUE STRATEGIES 83e66f82-0abf-48f4-96bc-6b3fd01a45d9 Q3 RED+BLUE STRATEGIES 400693064 COHERUS BIOSCIENCES 2023 third_quarter PHA Issues related to drug shortages in the United States and the role biosimilars can play. Issues related to cancer care and developing both biosimilar and novel treatments to fight disease. Issues related to advancing biosimilars in the health care market place to increase access and efficacy of life saving drugs. Support for encouraging the development, manufacturing and distribution of American-made biosimilars and other related products. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2023-10-07T16:03:52-04:00
3046053 HOLLAND & KNIGHT LLP a47e6d08-3b8a-4b0e-a669-7ca5ac6e57b9 Q3 HOLLAND & KNIGHT LLP 18466 VIATRIS INC 2023 third_quarter PHA Increasing Transparency in Generic Drug Applications Act, (S. 775), Part D Formulary Design; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; PEPFAR; Drug Shortages; Medicaid Generics Penalty. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-10-08T12:56:58-04:00
3047104 INDEPENDENT PHARMACY COOPERATIVE 3cc56634-7aba-4a80-993f-ea796bc5bb33 Q3 INDEPENDENT PHARMACY COOPERATIVE 313098 INDEPENDENT PHARMACY COOPERATIVE 2023 third_quarter PHA IPC supports Drug Transparency in Medicaid Act (H.R. 1613) ICP supports Promoting Access to Treatments and Increasing Extremely Needed Transparent (PATIENT) Act (HR 3561) IPC supports Drug Transparency in Medicaid Act (S. 1038) IPC supports The Modernizing and Ensuring PBM Accountability Act (S 2973) IPC supports Pharmacy and Medically Underserved Areas Enhancement Act (S 1491) IPC supports Protecting Patients Access to Pharmacy Act (S. 2052) IPC supports The Health Care Price Transparency Act (H.R. 4822) IPC supports Lower Cost, More Transparency Act (LCMT) (H.R. 5378) IPC supports Protecting Patients Against PBM Abuses Act (H.R. 2880) IPC Transparency and Fairness for Pharmacies Act (H.R. 5393) IPC supports Senate Bi-Partisan Working Group for 340B Reform - RFI response. IPC Supports FDA - Development of Small Dispensers Assessment Under the Drug Supply Chain Security Act; Request for Comments (FDA-2023-N-3103) IPC supports the Inflation Reduction Act of 2022 and CMS implementation. IPC opposes S. 1339 Pharmacy Benefits Reform Act - because it may preempt state PBM laws relating to ERISA. IPC supports S. 1491 Pharmacy and Medically Underserved Areas Enhancement Act Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,SENATE   30000 0 0 2023-10-10T17:22:04-04:00
3047359 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 5af1da9d-ea6b-486c-8b19-b100437db149 Q3 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 27478 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 2023 third_quarter PHA H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 382, the Pandemic is Over Act; H.R. 2679, the Pharmacy Benefits Manager Accountability Act; H.R. 3008, the Drug Shortage Prevention Act; S. 1339, the Pharmacy Benefits Manager Reform Act; S. 1542, the Delinking Revenue from Unfair Gouging Act; H.R. 5142, the Vaccine Injury Compensation Modernization Act of 2023; H.R. 5143, the Vaccine Access Improvement Act of 2023; S. 2305, the Biosimilar Red Tape Elimination Act; H.R. 1173, the Patients Right to Know Their Medication Act of 2023; Proposed rule for Medication Guides: Patient Medication Information (Docket No. FDA-2019-N-5959); Implementation of Public Law 113-54, the Drug Quality and Security Act Centers For Disease Control & Prevention (CDC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   360000 0 0 2023-10-11T11:53:04-04:00
3047414 RAY ANDERSON 8ff4db64-5d60-4f74-8d1d-b065b1b3dc00 Q3 RAY ANDERSON 401105487 340B HEALTH 2023 third_quarter PHA Contract Pharmacy-No legislation yet 340B Transparency-No legislation yet Contract Pharmacy Protect 340B-340B Patients Act (not yet introduced) 340B Transparency-Opposition to H.R. 3290 (overly burdensome reporting legislation that distorts the 340B program) Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA) 15000   0 0 2023-10-11T13:01:47-04:00
3047481 PUBLIC CITIZEN 62687c95-b67d-403a-a220-a00b1d3c4d89 Q3 PUBLIC CITIZEN 32362 PUBLIC CITIZEN 2023 third_quarter PHA S.1476 Pharmaceutical Research Transparency Act, S.954 Affordable Insulin Now Act, Medicare drug price negotiation implementation; Bayh-Dole royalty-free rights and contractual reasonable pricing conditions, NDAA government owned medical invention licensing, research and development transparency, and other transactions authority justification, pay for delay reform; product hopping reform; citizen petition abuse reform; FDA prescription drug transparency, S.2220 PREVAIL Act; S. 79 Interagency Patent Coordination and Improvement Act; S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150 Affordable Prescriptions for Patients Act, We PAID Act Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office   75000 0 0 2023-10-11T14:31:22-04:00
3047579 KOUNTOUPES DENHAM CARR & REID, LLC 3902152f-a87d-41e2-8f73-0cf2b2706475 Q3 KOUNTOUPES DENHAM CARR & REID, LLC 320918 ABBOTT LABORATORIES 2023 third_quarter PHA Legislation to expand Medicare coverage to permanently include services provided by a pharmacist, including incidental services and supplies, related to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R. 1770/S.2477, the Equitable Community Access to Pharmacist Services Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-10-11T15:25:14-04:00
3047618 KOUNTOUPES DENHAM CARR & REID, LLC 983996fa-571c-4d57-87b0-49fb9f05e17e Q3 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2023 third_quarter PHA General issues related to Over-The-Counter (OTC) pharmaceutical supply chain. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2023-10-11T15:42:53-04:00
3047963 LUNGREN LOPINA LLC ce8d4a13-8084-4954-8520-542e4e2cf800 Q3 LUNGREN LOPINA LLC 401103314 AMPAC FINE CHEMICALS 2023 third_quarter PHA Fair treatment for US based pharmaceutical ingredients Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2023-10-12T10:29:45-04:00
3048469 KOUNTOUPES DENHAM CARR & REID, LLC fa3d9820-cada-4428-bd69-3b09779a5cb2 Q3 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) 2023 third_quarter PHA Issues related to the pharmaceutical supply chain, drug shortages, and national stockpiles, including H.R. 405, the Essential Medicines Strategic Stockpile Act of 2023. Issues related to drug pricing transparency. Legislation that would permanently provide Medicare coverage of services provided by a pharmacist, including incidental services and supplies relating to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R. 1770/S. 2477, The Equitable Community Access to Pharmacist Services Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-10-12T16:34:48-04:00
3048677 BLUE SHIELD OF CALIFORNIA 07c7db17-f475-4bab-ac12-f4de0c14f7d8 Q3 BLUE SHIELD OF CALIFORNIA 6518 BLUE SHIELD OF CALIFORNIA 2023 third_quarter PHA Matters related to pharmacy benefit manager reform. HOUSE OF REPRESENTATIVES,SENATE   120000 0 0 2023-10-12T19:39:27-04:00
3048865 WAKEFERN FOOD CORP. 2f185c71-1ab8-4983-ac49-6e5b83e233d8 Q3 WAKEFERN FOOD CORP. 400588798 WAKEFERN FOOD CORP. 2023 third_quarter PHA Protect Patient Access to Pharmacies Act (S. 2052) The measure addresses DIR/PBM reform, including: 1) Eliminating DIR fees 2) Establishing a rate floor for pharmacy reimbursements 3) Establishing standardized performance measures. HOUSE OF REPRESENTATIVES,SENATE     0 0 2023-10-13T10:50:06-04:00
3048871 DAVE KOLBE CONSULTING e6676d64-1d7d-4289-96ed-72047cf137cf Q3 DAVE KOLBE CONSULTING 401104329 PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION 2023 third_quarter PHA Inflation Reduction Act (IRA) - Opposing Expansion of IRA Bill's Drug Coverage. While understanding the intention to provide wider access to affordable medications, we believe this proposed expansion could have unintended negative consequences on employment with the prescription drug industry. Protecting Patients Against PBM Abuses Act (H.R. 2880) - Urging support of H.R. 2880. 2023 Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) - Oppose legislation to expand upon the recent bipartisan language in the draft to reintroduce the concept of "Reasonable Pricing" requirements. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2023-10-13T10:53:37-04:00
3048908 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER b2a10fc0-ecf7-4693-8976-8d96b03a45cc Q3 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 312496 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 2023 third_quarter PHA 340B Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE   36400 0 0 2023-10-13T11:09:16-04:00
3049397 BOLD STRATEGIES, LLC 52ea032f-f9be-437c-91cd-78252dfeef3a Q3 BOLD STRATEGIES, LLC 401104653 MORRIS & DICKSON CO., LLC 2023 third_quarter PHA Prescription drug issues generally. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2023-10-13T15:40:30-04:00
3049770 GOVERNMENT COUNSEL, LLC dd1ee305-4ebf-4537-b0e6-df59980b7308 Q3 GOVERNMENT COUNSEL, LLC 401105070 HEALTHCARE DISTRIBUTION ALLIANCE 2023 third_quarter PHA H.R. 501-Block, Report, And Suspend Suspicious Shipments Act. Legislative proposals to prevent and respond to drug shortages. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-10-14T12:46:09-04:00
3050056 TRUSYNERGY f36e2a95-1caa-48dd-9c8a-1649fc69b2ea Q3 TRUSYNERGY 401107715 BURRELL INTERNATIONAL GROUP LLC (ON BEHALF OF SHIONOGI INC.) 2023 third_quarter PHA Oversight of the Strategic National Stockpile to promote safer and more effective treatments in the stockpile; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; FY 24 LHHS appropriations; funding and incentives for MCM development; AMR issues HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2023-10-15T11:46:30-04:00
3050332 CORNERSTONE GOVERNMENT AFFAIRS, INC. 6174e9c7-d6be-45ba-88fa-278e77cbf53a Q3 CORNERSTONE GOVERNMENT AFFAIRS, INC. 75557 MICHIGAN HEALTH & HOSPITAL ASSOCIATION 2023 third_quarter PHA Advised on FY 24 Labor-Health and Human Services-Education appropriations; H.R. 5378, Lower Cost, More Transparency Act; Medicare reimbursement; Medicaid coverage and Medicaid supplemental payments; health care workforce issues; Rural Emergency Hospital designation; cancer drug shortages; Centers for Medicare & Medicaid Services Minimum Staffing Standards for Long-Term Care Facilities proposed rule. Engaged with Michigan congressional delegation offices. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2023-10-15T23:48:37-04:00
3050423 ARNOLD & PORTER KAYE SCHOLER LLP 6a889214-5c9e-474f-9d06-d2e1680cf1e1 Q3 ARNOLD & PORTER KAYE SCHOLER LLP 4301 NOVO NORDISK, INC. 2023 third_quarter PHA Issues related to pharmacy benefit managers and the 340B Program. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2023-10-16T08:48:25-04:00
3050608 UNIVERSITY OF IOWA 2b7dba95-e15e-4572-9848-52fca1321b09 Q3 UNIVERSITY OF IOWA 49191 UNIVERSITY OF IOWA 2023 third_quarter PHA N/A HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2023-10-16T10:24:44-04:00
3050745 FAEGRE DRINKER BIDDLE & REATH LLP ddd212e9-c294-46de-8d4a-909999f57ec2 Q3 FAEGRE DRINKER BIDDLE & REATH LLP 12631 ALLIANCE FOR SAFE ONLINE PHARMACIES (ASOP GLOBAL) 2023 third_quarter PHA Illicit prescription drug sales online; Rogue internet drug sellers; Dangers of counterfeit medicines; Risks of drug importation on patient safety; Domain name system accountability; S.3399, H.R. 6352 - Domain Reform for Unlawful Drug Sellers Act (DRUGS Act);S. 1843, H.R. 3429 - SHOPSAFE Act; S. 4858 - Cooper Davis Act. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2023-10-16T11:05:37-04:00
3050802 MCDERMOTT+ LLC 89333959-5d50-4ccd-8811-32d738cd996a Q3 MCDERMOTT+ LLC 401103287 CAMPAIGN FOR SUSTAINABLE DRUG PRICING 2023 third_quarter PHA Prescription drug pricing issues. Pricing of Covid 19 vaccines. H.R. 485 - the Protecting Health Care for All Patients Act. S. 775 - Increasing Transparency in Generic Drug Applications Act. S. 1214 - Retaining Access and Restoring Exclusivity Act. S. 1067 - Ensuring Timely Access to Generics Act. S. 935 - Fair Accountability and Innovative Research Drug Pricing Act of 2023. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2023-10-16T11:10:30-04:00
3050930 4C COMMUNICATIONS, INC. ae831e18-63f7-4eff-a3fe-d441bbfd25f2 Q3 4C COMMUNICATIONS, INC. 323717 HEALTHCARE LEADERSHIP COUNCIL 2023 third_quarter PHA Medicare Advantage, Healthcare Workers Resilience Act HOUSE OF REPRESENTATIVES,SENATE     0 0 2023-10-16T11:55:06-04:00
3051088 THE CONSILIO GROUP 8904d241-d9f5-4967-b4f0-9c70078d168c Q3 THE CONSILIO GROUP 400374717 PARATEK PHARMACEUTICALS 2023 third_quarter PHA Development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government, and military use Air Force, Dept of,Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE,U.S. Secret Service,White House Office 36000   0 0 2023-10-16T12:45:10-04:00
3051195 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION b91e584b-6abd-491b-8cc3-03394642be77 Q3 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 401103605 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 2023 third_quarter PHA Discussed issues related to drug shortages, pandemic preparedness, workforce development, advanced manufacturing, onshoring, and supply chains HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2023-10-16T13:45:09-04:00
3051269 LUPIN PHARMACEUTICALS INC d6fc32b1-4034-4db4-a080-7d9ba6ebd1da Q3 LUPIN PHARMACEUTICALS INC 401104766 LUPIN PHARMACEUTICALS INC 2023 third_quarter PHA Issues related to finished dose pharmaceutical reimbursement, pricing transparency, and drug disposal. HOUSE OF REPRESENTATIVES,SENATE   105000 0 0 2023-10-16T14:17:04-04:00
3051354 EMERGENT STRATEGIES ba42b329-7fd6-4868-9e1c-3b7e864a04a4 Q3 EMERGENT STRATEGIES 401104778 GENBIOPRO, INC. 2023 third_quarter PHA FDA Approval of generic mifepristone and related Risk Evaluation Mitigation Strategies (REMS). HOUSE OF REPRESENTATIVES,SENATE 35000   0 0 2023-10-16T14:54:23-04:00
3051415 BLUECROSS BLUESHIELD OF TENNESSEE 7ba744de-8fa8-4de1-a271-02af81d17a9d Q3 BLUECROSS BLUESHIELD OF TENNESSEE 6440 BLUECROSS BLUESHIELD OF TENNESSEE 2023 third_quarter PHA Insulin Act; Insulin Out of Pocket Charges; Pharmacy Benefit Managers; Delinking PBM language S 954 - Affordable Insulin Now Act A bill to provide for appropriate cost-sharing for insulin products covered under private health plans and to establish a program to support health care providers and pharmacies in providing discounted insulin products to uninsured individuals. S. 1339 - Pharmacy Benefit Manager Reform Act To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage S.127 - PBM Transparency Act of 2023 To prevent unfair and deceptive acts or practices and the dissemination of false information related to PBM services for Rx drugs, etc. HOUSE OF REPRESENTATIVES,SENATE   485000 0 0 2023-10-16T15:18:37-04:00
3051638 BROWNSTEIN HYATT FARBER SCHRECK, LLP b47cf11b-44bd-457e-927f-48711eec7427 Q3 BROWNSTEIN HYATT FARBER SCHRECK, LLP 7257 WALGREEN CO. 2023 third_quarter PHA Pharmacist provider status Issues related to drug pricing Implementation of the Inflation Reduction Act of 2022 Issues related to access and distribution of pharmaceutical products HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-10-16T16:24:58-04:00
3052100 KNIGHT CAPITOL CONSULTANTS 5bca2ba5-c5cf-4b6a-b650-db6e3c72864a Q3 KNIGHT CAPITOL CONSULTANTS 40036301 REGENXBIO 2023 third_quarter PHA Development of legislation that would affect the research, regulation or pricing of biopharmaceuticals, including implementation of the Inflation Reduction Act (no specific legislation) SENATE 60000   0 0 2023-10-16T22:53:51-04:00
3052289 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 87f7cf1c-e63d-4922-a33f-c542dd7be56c Q3 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 29403 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2023 third_quarter PHA OTC Switch - general advocacy on Prescription to Over-the-Counter Switch of medications and ingredients. Proposed rule for Nonprescription Drug Product with an Additional Condition for Nonprescription Use H.R. 2964/S. 1350 - The Wastewater Infrastructure Pollution Prevention and Environmental Safety Act or the WIPPES Act FDA Nonprescription Drugs Advisory Committee Meeting on Phenylephrine Activities related to Over-the-Counter Monograph Drug User Fee Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 160780   0 0 2023-10-17T10:06:03-04:00
3052396 PANNONE LOPES DEVEREAUX & O'GARA LLC fef434ea-be7b-4226-b4e0-014ec99b8cca Q3 PANNONE LOPES DEVEREAUX & O'GARA LLC 401105501 AMGEN 2023 third_quarter PHA Prescription drug pricing.   9000   0 0 2023-10-17T10:31:41-04:00
3052399 ARENTFOX SCHIFF LLP 6d932d1c-058b-40fb-a9e3-1e3a0ed72057 Q3 ARENTFOX SCHIFF LLP 4208 AMERICAN PHARMACY COOPERATIVE, INC. 2023 third_quarter PHA Prescription drug pricing generally S. 2973 (Modernizing and Ensuring PBM Accountability Act), all provisions HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2023-10-17T10:33:05-04:00
3052678 ALB SOLUTIONS 5f454734-7cb5-4b62-9280-b12400148cea Q3 ALB SOLUTIONS 401105973 BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2023 third_quarter PHA Issues related to regulatory and legislative developments regarding biosimilars. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2023-10-17T11:36:40-04:00
3052680 BUCHANAN INGERSOLL & ROONEY PC 0903192e-6775-4530-9df1-01c873205aa6 Q3 BUCHANAN INGERSOLL & ROONEY PC 55291 AIM IMMUNOTECH INC. 2023 third_quarter PHA Strategy development and implementation of company's federal government relations initiatives relating to research and development of therapeutics. Work with Department of Defense on Ebola countermeasures. Comprehensive Access to Resources and Education (CARE) For Long COVID Act Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2023-10-17T11:36:55-04:00
3052771 AMERICAN VETERINARY MEDICAL ASSOCIATION 204155bc-e423-440b-9f27-12b6847880ee Q3 AMERICAN VETERINARY MEDICAL ASSOCIATION 3630 AMERICAN VETERINARY MEDICAL ASSOCIATION 2023 third_quarter PHA H.R. 1418/ S. 1844 Animal Drug User Fee Act/ Animal Generic Drug User Fee Act reauthorization H.R. 1839/S. 993 Combatting Illicit Xylazine Act H.R. 4531 SUPPORT Act Review of zootechnical animal food substances language as an amendment to the Animal Drug User Fee Amendments of 2023 H.R. 1683 Generic Animal Drug Advancement Act, all provisions Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE   270000 0 0 2023-10-17T11:52:31-04:00
3052827 SHIONOGI INC. f2a58288-ab31-48ce-914f-d6bcf82a2b12 Q3 SHIONOGI INC. 401107081 SHIONOGI INC. 2023 third_quarter PHA Pandemic preparedness; Antimicrobial resistance; Pandemic and All Hazards Preparedness Act (PAHPA) Reauthorization; PASTEUR Act (H.R. 2940, S. 1355) Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   90000 0 0 2023-10-17T12:05:03-04:00
3052933 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 83fca7c6-8250-4ca6-b441-117a780f469c Q3 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 26672 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2023 third_quarter PHA H.R. 1613 Drug Price Transparency in Medicaid Act of 2023 H.R. 1770 The Equitable Community Access to Pharmacist Services Act H.R. 2880 Protecting Patients Against PBM Abuses Act H.R. 2816 The PBM Sunshine and Accountability Act H.R. 3561 The Patient Act H.R. 4365 Department of Defense Appropriations Act, 2024 H.R. 5378 Lower Costs More Transparency H.R. 5393 To amend title XVIII of the Social Security Act to ensure fair assessment of pharmacy performance and quality under Medicare part D, and for other purposes. H.R. 5400 The Neighborhood Options for Patients Buying Medicines (NO PBMs) Act S. 113 Prescription Pricing for the People Act S. 127 Pharmacy Benefit Manager Transparency Act S. 1038 Drug Price Transparency in Medicaid Act of 2023 S. 1339 Pharmacy Benefit Manager Reform Act S. 1491 Pharmacy and Medically Underserved Areas Enhancement Act S. 2052 Protect Patient Access to Pharmacies Act S. 2436 The Neighborhood Options for Patients Buying Medicines (NO PBMs) Act S. 2666 ECAPS 2.0 Act S. 2973 Modernizing & Ensuring PBM Accountability (MEPA) Act HOUSE OF REPRESENTATIVES,SENATE   370000 0 0 2023-10-17T12:27:17-04:00
3053207 TRAVERE THERAPEUTICS 48bf7db4-7129-4824-9060-760d422c1970 Q3 TRAVERE THERAPEUTICS 401104190 TRAVERE THERAPEUTICS 2023 third_quarter PHA Legislation regarding drug pricing, value, and reimbursement including implementation of the Inflation Reduction Act of 2022. The Safe Step Act, H.R. 2630/S. 652. The HELP Copays Act, H.R. 830/S. 1375. H.R. 5339, the Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act). Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   175000 0 0 2023-10-17T13:22:17-04:00
3053375 BROYDRICK & ASSOCIATES 3f4b0995-7a18-41b0-bffa-9385e81d4ed9 Q3 BROYDRICK & ASSOCIATES 7268 TONIX PHARMACEUTICALS 2023 third_quarter PHA Funding for drug treatment for PTSD and COVID-19, BARDA appropriations. Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2023-10-17T13:58:58-04:00
3053517 TWENTY-FIRST CENTURY GROUP, INC. e045eb76-196b-470f-96b0-10fda941b555 Q3 TWENTY-FIRST CENTURY GROUP, INC. 38687 CARDINAL HEALTH, INC. 2023 third_quarter PHA Issues related to the distribution and sale of pharmaceutical and medical products and services; medical and public health preparedness; COVID-19 pandemic response; and the healthcare supply chain. HOUSE OF REPRESENTATIVES,SENATE 24000   0 0 2023-10-17T14:35:23-04:00
3054126 BROWNSTEIN HYATT FARBER SCHRECK, LLP 107c6ded-81e3-4036-8f1d-41324c7c0144 Q3 BROWNSTEIN HYATT FARBER SCHRECK, LLP 7257 ROMARK GLOBAL PHARMA, LLC 2023 third_quarter PHA Issues regarding Biomedical Advanced Research and Development Authority Covid-19 Therapeutics' Pandemic All Hazards Preparedness Act HOUSE OF REPRESENTATIVES,SENATE     0 0 2023-10-17T17:00:59-04:00
3054592 FORBES-TATE 5ac93b87-d323-4ffd-9cde-317345bdc6bf Q3 FORBES-TATE 400976792 PHRMA 2023 third_quarter PHA Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169). HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2023-10-17T20:04:06-04:00
3054712 PORT SIDE STRATEGIES, LLC 643867a9-3dec-44e5-b643-71dc56da589f Q3 PORT SIDE STRATEGIES, LLC 401105394 SOCIAL SECURITY WORKS 2023 third_quarter PHA Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2023-10-17T21:05:38-04:00
3054717 PORT SIDE STRATEGIES, LLC ac551ec4-8c32-48f5-a455-8727c7641269 Q3 PORT SIDE STRATEGIES, LLC 401105394 NEW VENTURE FUND 2023 third_quarter PHA Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022. S.2305 - Biosimilar Red Tape Elimination Act - in support. S. 2157 - A bill to repeal prescription drug price control provisions of the Inflation Reduction Act - opposed. H.R.4895 - Lowering Drug Costs for American Families Act - in support. HOUSE OF REPRESENTATIVES,SENATE,White House Office     0 0 2023-10-17T21:07:22-04:00
3054720 PORT SIDE STRATEGIES, LLC 32c2a356-71ca-452a-bb3f-93e8b1060977 Q3 PORT SIDE STRATEGIES, LLC 401105394 CENTER FOR HEALTH AND DEMOCRACY 2023 third_quarter PHA Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022. S.1339 - Pharmacy Benefit Manager Reform Act - in support. S.2973 - Modernizing and Ensuring PBM Accountability Act - in support. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2023-10-17T21:09:01-04:00
3054786 FORBES-TATE 6b0f7f1c-709f-4641-b2af-af57d41b5a8c Q3 FORBES-TATE 400976792 INDEPENDENT PHARMACY COOPERATIVE 2023 third_quarter PHA Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2023-10-17T21:23:06-04:00
3054841 HEALTHSPERIEN d18acc88-454f-4a57-99bf-1ea947681914 Q3 HEALTHSPERIEN 401103150 EXACT CARE PHARMACY 2023 third_quarter PHA Advocate for codifying definition for long-term care pharmacy. (S. 1574) Advocate for inclusion of chronic care pharmacy in CMS and CMMI payment approaches Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2023-10-17T22:03:24-04:00
3054976 PATIENTS RISING NOW 1e754a03-ae98-49e7-84c7-108a5a779517 Q3 PATIENTS RISING NOW 401107039 PATIENTS RISING NOW 2023 third_quarter PHA Accelerated Approval. Pharmacy Benefits Managers. S.127 - Pharmacy Benefit Manager Transparency Act of 2023. Medical patents. Alternative Funding Vendors. H.R.2816 - PBM Sunshine and Accountability Act. H.R.2880 - Protecting Patients from PBM Abuses Act. H.R.3839 - Increasing Transparency in Generic Drug Applications Act. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE   30000 0 0 2023-10-18T01:10:24-04:00
3055121 FORBES-TATE 485a3939-3a0e-4937-a70f-b9cf22cd077b Q3 FORBES-TATE 400976792 CALIFORNIA LIFE SCIENCES ASSOCIATION 2023 third_quarter PHA Issues related to the life sciences industry; Issues related to drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169). HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2023-10-18T09:02:34-04:00
3055279 SQUIRE PATTON BOGGS c36f7b51-7514-4cda-ba46-5dc482d687a9 Q3 SQUIRE PATTON BOGGS 30906 SK HYNIX AMERICA, INC. 2023 third_quarter PHA Monitor proposals and issues related to biopharmaceuticals. HOUSE OF REPRESENTATIVES,SENATE 110000   0 0 2023-10-18T09:44:11-04:00
3055532 AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY cda689e5-8790-41fd-933a-96541dad16c7 Q3 AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY 3402 AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY 2023 third_quarter PHA compounding of bulk moxifloxacin Food & Drug Administration (FDA)   148478 0 0 2023-10-18T10:30:40-04:00
3055657 TARPLIN, DOWNS & YOUNG, LLC f7abb306-521c-4858-adda-0182fd281a7e Q3 TARPLIN, DOWNS & YOUNG, LLC 304736 HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) 2023 third_quarter PHA Opioid Abuse - General issues related to opioid abuse and access to medication assisted treatment HR 501 Halt, Block, and Suspend Suspicious Orders HR 1770 - Equitable Community Access to Pharmacist Services Act Implementation of Public Law 113-54 (DSCSA) Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office 80000   0 0 2023-10-18T10:58:00-04:00
3056325 FAEGRE DRINKER BIDDLE & REATH LLP 4d53bbcf-3ffc-411b-a5e9-6e1c516fa223 Q3 FAEGRE DRINKER BIDDLE & REATH LLP 12631 CIRCLE MEDICAL 2023 third_quarter PHA Issues related to telehealth/telemedicine and pharmacies.   20000   0 0 2023-10-18T12:56:11-04:00
3056341 WINNING STRATEGIES WASHINGTON 541f44a9-7d87-4c01-b5e9-d20cb48a35e3 Q3 WINNING STRATEGIES WASHINGTON 50796 KALEO 2023 third_quarter PHA Pharmaceutical drug development, including epinephrine for anaphylaxis; drug access and affordability issues HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2023-10-18T12:57:14-04:00
3056683 HARMONY BIOSCIENCES af6f1bc1-f26e-4bbb-afe1-d894b8ee2745 Q3 HARMONY BIOSCIENCES 401105020 HARMONY BIOSCIENCES 2023 third_quarter PHA Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications; H.R.1350, Camerons Law; FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R. 1805, Leos Law; Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy; H.R. 830, S.1375, The HELP Copays Act; H.R. 5539, The ORPHAN Cures Act. HOUSE OF REPRESENTATIVES,SENATE   250000 0 0 2023-10-18T13:48:55-04:00
3056846 DESIMONE CONSULTING, LLC b68d21ab-9d98-476d-9ae5-104976e8eedf Q3 DESIMONE CONSULTING, LLC 400931695 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) 2023 third_quarter PHA Issues related to patient access and pricing. Issues related to policy changes to Medicare Part D. Issues related to PBM reform; H.R. 2880, Protecting Patients Against PBM Abuses Act and H.R.5376, Share the Savings with Seniors Act. Issues related to 340B reform. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2023-10-18T14:05:21-04:00
3057548 THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH f0bff0af-a21b-458b-90af-22a905b1841a Q3 THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH 401104060 THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH 2023 third_quarter PHA Lobbying to improve prescription drug affordability and accessibility for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.2360/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Led an digital campaign to allow constituents to write their members of Congress in support of this legislation. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   70000 0 0 2023-10-18T15:35:36-04:00
3057566 MASSACHUSETTS MEDICAL SOCIETY 6309ede5-4811-45a8-b90e-e9b71e12d3ae Q3 MASSACHUSETTS MEDICAL SOCIETY 23975 MASSACHUSETTS MEDICAL SOCIETY 2023 third_quarter PHA Prescription Drug Pricing Issues related to prescription drug pricing - no specific bill S. 470/HR 977, The Patient Access to Higher Quality Health Care Act HOUSE OF REPRESENTATIVES,SENATE   40000 0 0 2023-10-18T15:36:58-04:00
3057988 BLUE CROSS AND BLUE SHIELD OF KANSAS, INC. fb208931-9bac-47fd-877c-c34d8386efb0 Q3 BLUE CROSS AND BLUE SHIELD OF KANSAS, INC. 323876 BLUE CROSS AND BLUE SHIELD OF KANSAS INC 2023 third_quarter PHA Insulin Out of Pocket Charges; Finance PBNM Framework Proposals; Covid Vaccines S. 150 - Affordable Prescriptions for Patients Act of 2023 A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. John Cornyn (R-TX) S. 127 - Pharmacy Benefit Manager Transparency Act of 2023 A bill to prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes. Sponsor: Sen. Maria Cantwell (D-WA) S.1067 - Ensuring Timely Access to Generics Act of 2023 To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. Sponsor: Sen. Shaheen, Jeanne [D-NH] S.1114 - Expanding Access to Low-Cost Generics Act of 2023 To amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period. Sponsor: Sen. Smith, Tina [D-MN] S.1269 - INSULIN Act of 2023 To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Sponsor: Sen. Shaheen, Jeanne [D-NH] S.1339 - Pharmacy Benefit Manager Reform Act To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage. Sponsor: Sen. Sanders, Bernard [I-VT] S.2305 - Biosimilar Red Tape Elimination Act To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Sponsor: Sen. Lee, Mike [R-UT] Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   10000 0 0 2023-10-18T16:39:04-04:00
3058037 NATIONAL RURAL HEALTH ASSOCATION 88e70eac-dcfe-48e2-88e9-72e34e46c680 Q3 NATIONAL RURAL HEALTH ASSOCATION 53048 NATIONAL RURAL HEALTH ASSOCATION 2023 third_quarter PHA Rural Health Care Policy and 340b Program Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   8591 0 0 2023-10-18T16:45:25-04:00
3058112 CAPITOL COUNSEL LLC cbe19398-cf0f-498a-9cf6-6646d4d90887 Q3 CAPITOL COUNSEL LLC 313715 EMD SERONO, INC. 2023 third_quarter PHA Issues regarding the availability and pricing of prescription drugs. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2023-10-18T16:54:31-04:00
3058267 THORN RUN PARTNERS 73cc9c1a-74f4-4712-8754-76c870b85066 Q3 THORN RUN PARTNERS 400534596 AMERICAN POLICY VENTURES ACTION 2023 third_quarter PHA Issues and legislation related to reduction of prescription medication for Americans. HOUSE OF REPRESENTATIVES,SENATE,White House Office 30000   0 0 2023-10-18T17:15:57-04:00
3058329 WALGREEN COMPANY 8714f57d-1fe6-495e-8647-980c84d21fe8 Q3 WALGREEN COMPANY 309071 WALGREEN COMPANY 2023 third_quarter PHA H.R. 7213/S. 2477- Equitable Community Access to Pharmacist Services Act: Issues related to access to pharmacist services. Public Law: 109-148 - Public Readiness and Emergency Preparedness Act (PREP Act): Issues related to COVID testing and vaccinations. H.R. 2503/S. 1701 - NIH Clinical Trial Diversity: Issues related to NIH funding for programs to increase diversity in clinical trials. HOUSE OF REPRESENTATIVES,SENATE   940000 0 0 2023-10-18T17:22:56-04:00
3058440 HARPER DOWNING db041ea8-dad3-4d42-b250-3b467af0317e Q3 HARPER DOWNING 401107879 HUMANETICS CORPORATION 2023 third_quarter PHA Pandemic and All-Hazards Preparedness Act reauthorization HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2023-10-18T17:36:46-04:00
3058546 NELSON MULLINS RILEY & SCARBOROUGH 67964581-7c92-4526-8af0-c4b6201a8b74 Q3 NELSON MULLINS RILEY & SCARBOROUGH 285871 TIDELANDS HEALTH 2023 third_quarter PHA Issues related to the 340B Drug Pricing Program SENATE 40000   0 0 2023-10-18T17:56:57-04:00
3058597 INVARIANT LLC 76b9289a-8560-4aa3-8404-81d648af8ce2 Q3 INVARIANT LLC 314237 SK HYNIX AMERICA INC. 2023 third_quarter PHA Monitor proposals and issues related to biopharmaceuticals. HOUSE OF REPRESENTATIVES,SENATE 140000   0 0 2023-10-18T18:06:58-04:00
3058629 KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) 1bd08551-ff3e-46e0-a98a-405a43ccd65a Q3 KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) 401105192 CVS HEALTH 2023 third_quarter PHA Issues encompassing general education regarding the pharmacy benefit manager/pharmacy industry. Issues related to access and affordability of healthcare, prescription drugs, and generic drugs. HOUSE OF REPRESENTATIVES,SENATE 25000   0 0 2023-10-18T18:20:31-04:00
3058645 BROWNSTEIN HYATT FARBER SCHRECK, LLP 8868806b-6516-413a-90d6-edb2c00d8a0d Q3 BROWNSTEIN HYATT FARBER SCHRECK, LLP 7257 LILLY USA, LLC 2023 third_quarter PHA Issues related to the pharmaceutical industry Issues related to Inflation Reduction Act Implementation HOUSE OF REPRESENTATIVES 60000   0 0 2023-10-18T18:27:59-04:00
3058835 E3 STRATEGIC CONSULTING GROUP 142398ed-3cc3-4a66-8a39-db360db2cae2 Q3 E3 STRATEGIC CONSULTING GROUP 401104104 PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION 2023 third_quarter PHA Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing, and employment issues, generally; S.127 - Pharmacy Benefit Manager Transparency Act of 2023; S.113 - Prescription Pricing for the People Act of 2023; H.R.830 - HELP Copays Act; S. 1542 - Delinking Revenue from Unfair Gouging Act (a/k/a The DRUG Act"); HR 4895 - H.R. 4895: Lowering Drug Costs for American Families Act; H.R. 2880: Protecting Patients Against PBM Abuses Act. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2023-10-18T20:19:19-04:00
3058902 POLARIS GOVERNMENT RELATIONS, LLC 688f18af-72e4-48b1-911f-797765350f14 Q3 POLARIS GOVERNMENT RELATIONS, LLC 307730 CIGNA CORPORATION 2023 third_quarter PHA Drug pricing and issues facing the pharmacy benefit manager industry generally HOUSE OF REPRESENTATIVES,SENATE 90000   0 0 2023-10-18T20:52:24-04:00
3059099 MASON STREET CONSULTING, LLC b62f6348-4984-4dec-bf72-be0464fe4751 Q3 MASON STREET CONSULTING, LLC 401105150 CAPITAL RX INC. 2023 third_quarter PHA PBM Reform. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2023-10-18T23:56:28-04:00
3059165 VAN SCOYOC ASSOCIATES ab7f72e9-d684-4c28-b9cd-bd4e77aabc17 Q3 VAN SCOYOC ASSOCIATES 39837 ZEBRA TECHNOLOGIES CORP. 2023 third_quarter PHA H.R.2670/S.2226, National Defense Authorization Act for Fiscal Year 2024, Temperature monitoring technology S.2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2024, Temperature monitoring related issues HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2023-10-19T05:23:11-04:00
3059421 ELI LILLY AND COMPANY 9c6cfdbd-c193-4a1a-98fd-f20d7f9a9248 Q3 ELI LILLY AND COMPANY 13392 ELI LILLY AND COMPANY 2023 third_quarter PHA Hospital discounts; 340B program HOUSE OF REPRESENTATIVES,SENATE   2301360 0 0 2023-10-19T08:21:30-04:00
3059670 FAEGRE DRINKER BIDDLE & REATH LLP a928a3b3-8084-4fa1-b6b0-45fd48a2cd61 Q3 FAEGRE DRINKER BIDDLE & REATH LLP 12631 VERDE ENVIRONMENTAL TECHNOLOGIES, INC. 2023 third_quarter PHA Drug safety. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA) 20000   0 0 2023-10-19T09:27:30-04:00
3059736 MARSHALL & POPP, LLC 94ba18df-c703-4d28-83cd-8eb48063afa8 Q3 MARSHALL & POPP, LLC 401105121 AMGEN USA INC. 2023 third_quarter PHA Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-10-19T09:34:50-04:00
3059819 CHRISTIANACARE 0e531751-10fd-464d-b951-6984a826d187 Q3 CHRISTIANACARE 401105790 CHRISTIANACARE 2023 third_quarter PHA Issues related to the 340B Drug Discount Program Support for the Protect 340B Act of 2023 (H.R. 2534) HOUSE OF REPRESENTATIVES,SENATE     0 0 2023-10-19T09:43:07-04:00
3059855 MARSHALL & POPP, LLC 3cefa065-7ccb-4d4b-9ca0-e8108ea2e77c Q3 MARSHALL & POPP, LLC 401105121 GENENTECH, INC. 2023 third_quarter PHA Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-10-19T09:48:22-04:00
3059914 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 97ce6e5d-30ee-49bd-9b0e-d5666099a0c3 Q3 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 3457 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 2023 third_quarter PHA Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. The PROTECT 340B Act (H.R. 2534), provisions related to enforcement of the 340B Drug Pricing Program. Issues related to pharmacy residency funding (generally, no specific legislation). Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation). Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   280000 0 0 2023-10-19T09:58:10-04:00
3059919 MARSHALL & POPP, LLC 01965ea4-b7f2-4932-9a7e-65a6ac2e5ac2 Q3 MARSHALL & POPP, LLC 401105121 PFIZER, INC. 2023 third_quarter PHA Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-10-19T09:59:00-04:00
3059933 MARSHALL & POPP, LLC 7fa314ae-a743-43d7-b6b2-4430f798b248 Q3 MARSHALL & POPP, LLC 401105121 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2023 third_quarter PHA Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development and distribution. Issues related to insulin pricing. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2023-10-19T10:00:52-04:00
3059945 MARSHALL & POPP, LLC feaccfcc-3a6d-41c2-9135-3f1266cc328a Q3 MARSHALL & POPP, LLC 401105121 SANOFI U.S. SERVICES, INC. 2023 third_quarter PHA Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development, distribution and injury compensation. Issues related to insulin pricing. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-10-19T10:01:48-04:00
3060416 BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. 6d96ffd8-fb59-475f-8578-ff22e7905366 Q3 BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. 6382 BLUE CROSS AND BLUE SHIELD OF FLORIDA INC 2023 third_quarter PHA Insulin Out of Pocket Charges; Prescription Drug Pricing; PBM Proposals; COVID Vaccines S 127 (118th Congress), Pharmacy Benefit Manager Transparency Act of 2023, by Sen. Maria Cantwell (D-WA). To prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes. S 150 (118th Congress), Affordable Prescriptions for Patients Act of 2023, by Sen. John Cornyn (R-TX). To amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. S 1067 (118th Congress), Ensuring Timely Access to Generics Act of 2023, by Sen. Jeanne Shaheen (D-NH). To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. S 1114 (118th Congress), Expanding Access to Low-Cost Generics Act of 2023, by Sen. Tina Smith (D-NH). To amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period. S 1269 (118th Congress), INSULIN Act of 2023, by Sen. Jeanne Shaheen (D-NH). To reduce the price of insulin and provide for patient protections with respect for the cost of insulin. S 1339 (118th Congress), Pharmacy Benefit Manager Reform Act, by Sen. Bernie Sanders (I-VT). To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage. S 2305 (118th Congress), Biosimilar Red Tape Elimination Act, by Sen. Mike Lee (R-UT). To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office   120000 0 0 2023-10-19T11:07:14-04:00
3060451 FAEGRE DRINKER BIDDLE & REATH LLP 5976583d-6800-46cf-aa1f-cd9db21385bd Q3 FAEGRE DRINKER BIDDLE & REATH LLP 12631 NATIONAL ASSOCIATION OF BOARDS OF PHARMACY 2023 third_quarter PHA Medication safety, pharmacy regulation and licensure, drug supply chain security, and combatting the opioid epidemic; Prescription drug monitoring programs; HR 501 Block, Report, and Suspend Suspicious Shipments Act; Ryan Haight Act/DEA rule on telehealth. Drug Enforcement Administration (DEA),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE 40000   0 0 2023-10-19T11:09:30-04:00
3060486 GUIDEWELL MUTUAL HOLDING CORPORATION 3b30212e-e9a5-41f2-91d0-fe283e7ea7db Q3 GUIDEWELL MUTUAL HOLDING CORPORATION 401103191 GUIDEWELL MUTUAL HOLDING CORPORATION 2023 third_quarter PHA Insulin Out of Pocket Charges; Prescription Drug Pricing; PBM Proposals; COVID Vaccines S 127 (118th Congress), Pharmacy Benefit Manager Transparency Act of 2023, by Sen. Maria Cantwell (D-WA). To prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes. S 150 (118th Congress), Affordable Prescriptions for Patients Act of 2023, by Sen. John Cornyn (R-TX). To amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. S 1067 (118th Congress), Ensuring Timely Access to Generics Act of 2023, by Sen. Jeanne Shaheen (D-NH). To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. S 1114 (118th Congress), Expanding Access to Low-Cost Generics Act of 2023, by Sen. Tina Smith (D-NH). To amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period. S 1269 (118th Congress), INSULIN Act of 2023, by Sen. Jeanne Shaheen (D-NH). To reduce the price of insulin and provide for patient protections with respect for the cost of insulin. S 1339 (118th Congress), Pharmacy Benefit Manager Reform Act, by Sen. Bernie Sanders (I-VT). To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage. S 2305 (118th Congress), Biosimilar Red Tape Elimination Act, by Sen. Mike Lee (R-UT). To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office     0 0 2023-10-19T11:12:19-04:00
3060522 FOLEY & LARDNER LLP df288bd3-0d61-4dd2-a4c0-f7c14b8c023f Q3 FOLEY & LARDNER LLP 15042 BLINK HEALTH LTD (A BERMUDA LIMITED COMPANY) 2023 third_quarter PHA Market-based solutions to drug pricing and chain pharmacy barriers to generic pharmaceutical price reduction. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2023-10-19T11:15:58-04:00

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);
Powered by Datasette · Queries took 2699.928ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API